A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral Nuvisertib (TP-3654) in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis

Sponsor:

Sumitomo Dainippon Pharma Oncology, Inc.

Sponsor Study ID:

BB1-TP-3654-102

CTO #:

104205

NCT Number:

NCT04176198

Phase:

I/II

Protocol Type:

Treatment

Age Group:

Adults

Disease Sites:

Other Hematopoietic

Study Objectives:

To identify the recommended Phase 2 dose (RP2D) of nuvisertib monotherapy. To determine the overall safety of nuvisertib monotherapy [Note: This objective is secondary in Phase 1]. To assess any preliminary clinical activity of nuvisertib monotherapy [Note: This objective is secondary in Phase 1].

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)